💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Incyte Corporation (INCY)
« Back to company indexINCY Chatter Timeline
Stock Ticker for INCY
Most Active Tweeters for INCY
| User | Tweets |
|---|---|
| @MarcJacksonLA | 13 |
| @mediasentiment | 9 |
| @FlashAlert_me | 6 |
| @Tickeron | 5 |
| @TradeWithAlerts | 5 |
Recent Tweets for INCY
 |
@CSIMarket $INCY #StockMarket #yte released second quarter of 2021 Eps on https://t.co/savSNTKlN1: Sales growth of 2.568 %, co… https://t.co/4x14NHYFYq 4:08am |
 |
@fintel_io Insider Dashyant Dhanak reports selling 389 shares of $INCY for a total cost of $30,143.61 https://t.co/14MCG8MJLZ August 4th 2021, 8:08pm |
 |
@MarcJacksonLA $INCY Despite FDA holdups, Incyte's still counting on timely Jakafi, ruxolitinib cream verdicts https://t.co/t5ISo206Xh August 4th 2021, 4:08pm |
 |
@OptionHunt Ticker $INCY Unusual Volume Detected: 12.55% over average August 4th 2021, 2:08pm |
 |
@AlertTrade REVERSALtoUP: $INCY Incyte Corporation Common Stock https://t.co/x5T1J7UFl4 ? TradeIdeas via ? https://t.co/VS8RO1bzXJ August 4th 2021, 2:08pm |
 |
@Jarvis_Alerts $INCY [Incyte]: SVB Leerink Maintains Underperform Lowers Price Target $70 --> 67 charts: courtesy of finviz https://t.co/PHM4D74Z7j August 4th 2021, 10:08am |
 |
@mediasentiment $INCY new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 60 August 4th 2021, 8:08am |
 |
@quantisnow $INCY ? SVB Leerink reiterated coverage on Incyte with a new price target https://t.co/GF4J7AWjdN 30s delayed. August 4th 2021, 8:08am |
 |
@EarningsAlley Incyte Corporation $INCY held an earnings call on 8/3/2021. Here are the highlights: August 3rd 2021, 8:08pm |
 |
@EdgarInsider Filing Alert, FORM 10-Q [Quarterly Report] available. $INCY INCYTE CORP https://t.co/nzSK7PdNwo August 3rd 2021, 8:08pm |
 |
@investor_feed $INCY 10-Q Incyte (3 Aug, 4:03pm) ? 2020 Q2 Earnings https://t.co/En3s0Xxlt1 #INCY #10Q #Incyte #Earnings August 3rd 2021, 8:08pm |
 |
@FlashAlert_me $INCY [15s. delayed] filed form 10-Q on August 03, 16:03:51 https://t.co/m3gQbiNxkC August 3rd 2021, 8:08pm |
|
@fintel_io $INCY / Incyte files form 10-Q https://t.co/Oc4NyYycjO August 3rd 2021, 8:08pm |
 |
@SiteFocusHQ $INCY Earnings Intelligence Analysis of recent earnings identified Incyte Corp. (NASDAQ: INCY ) business focus on… https://t.co/Msyw1tJHro August 3rd 2021, 6:08pm |
 |
@SeekingAlpha $INCY - Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q2 2021 Results - Earnings Call Transcript.… https://t.co/9zYYZ2veWY August 3rd 2021, 5:08pm |
|
@MarcJacksonLA $INCY Traders Purchase Large Volume of Incyte Call Options | https://t.co/NKb5pS3e1Y https://t.co/cQvMK3FWgg August 3rd 2021, 5:08pm |
|
@MarcJacksonLA $INCY Mizuho Maintains Hold Rating On Incyte, $95 PT https://t.co/ivVIq0gHyT August 3rd 2021, 5:08pm |
|
@MarcJacksonLA $LLY $INCY Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical… https://t.co/skFrtdBPSP August 3rd 2021, 5:08pm |
|
@MarcJacksonLA $INCY Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs | Business… https://t.co/t0Bin7YRDL August 3rd 2021, 5:08pm |
 |
@Briefingcom $INCY: Incyte beats by $0.06, beats on revs https://t.co/x1oaCq3Leo August 3rd 2021, 1:08pm |
|
@SeekingAlpha $INCY - Incyte Corporation 2021 Q2 - Results - Earnings Call Presentation. https://t.co/1JEflmRx38 #trading #business #finance August 3rd 2021, 12:08pm |
 |
@bjen07921 RT @Estimize: The most accurate $INCY estimate is from @bjen07921, beating 6 other analysts and the Wall Street Consensus - https://t.co/6U… August 3rd 2021, 12:08pm |
|
@mediasentiment $INCY new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 268 August 3rd 2021, 12:08pm |
 |
@MarketCurrents $INCY - Incyte tops Q1 forecast; Jakafi revenue outlook lowered https://t.co/kILKz0fggh August 3rd 2021, 11:08am |
 |
@StockPods $INCY Earnings Call Today: 8:00 AM EST Webcast: https://t.co/BBsuAJ5FVO Signup for the StockPods BETA now: https://t.co/Vma4E2hQ99 August 3rd 2021, 11:08am |
 |
@mehabecapital (Earnings) Incyte ( $INCY ) Actual.EPS=0.8 vs Est.EPS=0.575, Actual.Rev=705.7M vs Est.Rev=687.96M, Last Quote: $78.… https://t.co/WmWB12dBLk August 3rd 2021, 11:08am |
|
@mediasentiment $INCY new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 204 August 3rd 2021, 11:08am |
|
@EdgarInsider Filing for 8-K [Press/News Current Report] has been made with the SEC: $INCY INCYTE CORP https://t.co/OiX7nRVStP August 3rd 2021, 11:08am |
 |
@Estimize The most accurate $INCY estimate is from @bjen07921, beating 6 other analysts and the Wall Street Consensus - https://t.co/6UTwXMGq7f August 3rd 2021, 11:08am |
|
@Estimize $INCY beats the Estimize EPS Consensus by 1c and the Estimize Revenue Consensus by $18.92M. Reports FQ2 earnings of… https://t.co/UlGVsKBd1N August 3rd 2021, 11:08am |
|
@Estimize $INCY reports FQ2 earnings of 80c EPS and $705.71M Revs - https://t.co/WZGwom6PHd August 3rd 2021, 11:08am |
 |
@tradingwithmose Eli Lilly and Incyte announce results from an additional cohort of 101 adult patients from the COV-BARRIER trial. $LLY $INCY August 3rd 2021, 11:08am |
 |
@StockNewsBot2 $INCY Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs https://t.co/ej6NMTmQNN August 3rd 2021, 11:08am |
|
@FlashAlert_me $INCY [15s. delayed, acc.~90%, always check] Earnings Release August 03, 07:00:00: Q2: Non-GAAP EPS of $0.80, GAAP… https://t.co/8CWkeKgEq8 August 3rd 2021, 11:08am |
|
@FlashAlert_me $INCY [15s. delayed]: Issued Press Release on August 03, 07:00:00: Incyte Reports 2021 Second Quarter Financial Res… https://t.co/RnbDnRQFqB August 3rd 2021, 11:08am |
 |
@stock_titan $INCY Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs https://t.co/ryvrYdIFnx August 3rd 2021, 11:08am |
|
@quantisnow $INCY ? Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs… https://t.co/QdOejNIswD August 3rd 2021, 11:08am |
|
@MarketCurrents $LLY $INCY - Lilly, Incyte's baricitinib reduces deaths among COVID-19 patients on mechanical ventilation https://t.co/qoZzcYdJmi August 3rd 2021, 10:08am |
 |
@otcdynamics $INCY Lilly and Incyte’s baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical vent… https://t.co/xLjfuKCP66 August 3rd 2021, 10:08am |
|
@FlashAlert_me $INCY [15s. delayed]: Issued Press Release on August 03, 06:00:00: Lilly and Incyte's baricitinib reduced deaths am… https://t.co/mcUtPsTXgJ August 3rd 2021, 10:08am |
 |
@mikalche $INCY Lilly's COVID-19 drug reduces death risk in patients on mechanical ventilation August 3rd 2021, 10:08am |
 |
@sbwcws Eli Lilly, Incyte announce results from additional cohort of COV-BARRIER trial $LLY $INCY August 3rd 2021, 10:08am |
|
@StockNewsBot2 $LLY $INCY Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical… https://t.co/InLeCchOZs August 3rd 2021, 10:08am |
|
@stock_titan $LLY $INCY Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical… https://t.co/tJNB9Qv974 August 3rd 2021, 10:08am |
|
@quantisnow $INCY $LLY ? Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanic… https://t.co/4izvgkVL5H August 3rd 2021, 10:08am |
|
@mediasentiment $INCY new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 1170 August 3rd 2021, 5:08am |
 |
@ShortAlgoTrades $INCY Awaiting Short Signal. Chart by UltraAlgo for #INCY. https://t.co/ytXtk5seCn August 3rd 2021, 2:08am |
 |
@vimarblanco $INCY Waiting for Short signal on INCY. https://t.co/KLGcnlcETp August 2nd 2021, 10:08pm |
 |
@InsiderForms $INCY Insider Iyengar Vijay K has Sold 4,911 Shares. Title :EVP GPS BD; Licensing Total Cost: $384,482.19 Buy/Sell… https://t.co/UtFr9LhiEA August 2nd 2021, 8:08pm |
|
@fintel_io Insider Vijay K Iyengar reports selling 4,911 shares of $INCY for a total cost of $384,482.19 https://t.co/B4waVJbrNd August 2nd 2021, 8:08pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
DrugPatentWatch Video Training
Decision-making for generic drug entry and branded drug lifecycle management
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
This course answers the following questions to help you adapt:
- ✓ When will key drug patents expire?
- ✓ How can I find, evaluate, and plan for generic market entry opportunities?
- ✓ How can I find proprietary out-of-court settlements and deal terms?